JP2022502492A5 - - Google Patents

Info

Publication number
JP2022502492A5
JP2022502492A5 JP2021540380A JP2021540380A JP2022502492A5 JP 2022502492 A5 JP2022502492 A5 JP 2022502492A5 JP 2021540380 A JP2021540380 A JP 2021540380A JP 2021540380 A JP2021540380 A JP 2021540380A JP 2022502492 A5 JP2022502492 A5 JP 2022502492A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
thiamine
composition according
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021540380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502492A (ja
JP7856429B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/052608 external-priority patent/WO2020068755A1/en
Publication of JP2022502492A publication Critical patent/JP2022502492A/ja
Publication of JP2022502492A5 publication Critical patent/JP2022502492A5/ja
Priority to JP2024125670A priority Critical patent/JP2024161416A/ja
Application granted granted Critical
Publication of JP7856429B2 publication Critical patent/JP7856429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021540380A 2018-09-25 2019-09-24 骨髄増殖性疾患の治療法 Active JP7856429B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125670A JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US62/736,369 2018-09-25
US201862783076P 2018-12-20 2018-12-20
US62/783,076 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125670A Division JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Publications (3)

Publication Number Publication Date
JP2022502492A JP2022502492A (ja) 2022-01-11
JP2022502492A5 true JP2022502492A5 (cg-RX-API-DMAC7.html) 2022-10-03
JP7856429B2 JP7856429B2 (ja) 2026-05-11

Family

ID=69950867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540380A Active JP7856429B2 (ja) 2018-09-25 2019-09-24 骨髄増殖性疾患の治療法
JP2024125670A Pending JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125670A Pending JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Country Status (14)

Country Link
US (2) US20220031699A1 (cg-RX-API-DMAC7.html)
EP (1) EP3856169A4 (cg-RX-API-DMAC7.html)
JP (2) JP7856429B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210102192A (cg-RX-API-DMAC7.html)
CN (1) CN113286584A (cg-RX-API-DMAC7.html)
AU (1) AU2019346521B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005518A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000744A1 (cg-RX-API-DMAC7.html)
IL (1) IL281736A (cg-RX-API-DMAC7.html)
MA (1) MA53741A (cg-RX-API-DMAC7.html)
MX (2) MX2021003450A (cg-RX-API-DMAC7.html)
MY (1) MY209349A (cg-RX-API-DMAC7.html)
SG (1) SG11202103019WA (cg-RX-API-DMAC7.html)
WO (1) WO2020068755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
MA53745A (fr) * 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
EP4262770A1 (en) * 2020-12-16 2023-10-25 Impact Biomedicines, Inc. Dosing of fedratinib
EP4297750A1 (en) 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
US20240358722A1 (en) * 2021-09-14 2024-10-31 Impact Biomedicines, Inc. Methods of administering fedratinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
MX2016009974A (es) * 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
MA53745A (fr) 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2

Similar Documents

Publication Publication Date Title
JP6984024B2 (ja) Cyp3a4基質薬物による処置方法
JP2609968B2 (ja) グリシン/nmda受容体複合体の機能性拮抗剤による情緒障害の治療
TWI353835B (en) Novel methods for identifying improved, non-sedati
CN101563086B (zh) 睾酮和5-ht1a激动剂在治疗性功能障碍中的应用
KR20250136946A (ko) 트라디피턴트에 의한 치료 방법
JP2021526138A5 (cg-RX-API-DMAC7.html)
EP3010505A1 (en) Pharmaceutical combinations
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20060173074A1 (en) Treatment of restless legs syndrome
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
CN104039148A (zh) 组合als疗法
US12414940B2 (en) Method of treating malignant tumor by azabicyclic compound
JP2022541446A (ja) レビー小体型認知症を処置するための組成物および方法
WO2007000764A2 (en) Compositions and methods for enhancement of sexual function
CN101610760A (zh) 恶病质的治疗
US20120071464A1 (en) Method of treatment of obsessive compulsive disorder with ondansetron
US11166922B2 (en) Method for treating hyperhidrosis with dexmecamylamine
PL211211B1 (pl) Zestawienie propionylo-L-karnityny z sildenafilem, kompozycja farmaceutyczna je zawierająca i jego zastosowanie
US20090176857A1 (en) Use of Organic Compounds
JP6420923B1 (ja) 医薬
JPWO2017022787A1 (ja) 収縮力低下随伴性排尿筋過活動改善剤
WO2026100645A1 (en) Methods for treating vasomotor symptoms in breast cancer patients with fezolinetant
RU2283097C2 (ru) Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
Sano Finding the Balance: Review of Pharmacological Management of Orthostatic Hypotension in Patients With Parkinson's Disease
Dubin Antiarrhythmic medications